Fidia Farmaceutici, S.p.A.

18 articles about Fidia Farmaceutici, S.p.A.

• The Italian R&D Excellence at the American Urological Association's 2019 Annual Meeting

  5/3/2019

  Preliminary data show Oncofid®P-B is very well tolerated and has promising efficacy when administered for up to 12 consecutive weeks in BCG unresponsive/intolerant patients with bladder carcinoma in situ (CIS)

• Fidia Announces Presentation of New Data Evaluating HYMOVIS® (HYADD®4) Effects on Metalloprotease Inhibition at 2018 ACR/ARHP Annual Meeting

  10/23/2018

  Poster (Abstract 2004): “Effective Inhibition of Metalloproteases By a Viscosupplement Based on a Hyaluronic Acid Amide (HYADD®4)”

• Fidia Announces Presentation of New Data Evaluating HYMOVIS® Effects on Cartilage Volume and Type II Collagen Turnover at Osteoarthritis Research Society International (OARSI) World Congress Meeting

  4/25/2018

  April 25, 2018 10:00 UTC Fidia Announces Presentation of New Data Evaluating HYMOVIS ® Effects on Cartilage Volume and Type II Collagen Turnover at Osteoarthritis Research Society International (OARSI) World Congress Meeting Poster Title: “Hyaluronan Derivative Hymovis ® Increases Cartilage Volume and Type II Collagen Turnover in Osteoarthritis Knee: Data from MOKHA ( M RI, Bi O markers, K nee, H ymovis ®

• Fidia Announces Presentation of New Data on a Cartilage Explant Model at Orthopaedic Research Society (ORS) Annual Meeting

  3/9/2018

  Articular Cartilage Lubrication by HYADD®4 reduces tissue strains, chondrocyte death, and apoptosis

• Fidia Farmaceutici, S.p.A. Release: HYMOVIS: An Innovation In HA-Based Viscoelastic Hydrogel Technology In The Treatment Of Osteoarthritis Knee Pain

  5/8/2017

• Fidia Farmaceutici, S.p.A. Release: HYMOVIS Demonstrates Superior Biomechanical Lubricating Properties

  3/23/2017

• Fidia Farmaceutici, S.p.A. Presents New Data On Hymovis, A Breakthrough In Viscoelastic Technology, At The American Orthopaedic Society For Sports Medicine 2016 Annual Meeting

  7/6/2016

• Fidia Farmaceutici, S.p.A. Presents New Data On Hymovis, A Breakthrough In Viscoelastic Technology, At The American Orthopaedic Society For Sports Medicine 2016 Annual Meeting

  7/6/2016

• Fidia Farmaceutici, S.p.A. Introduces Hymovis, A Next-Generation Hyaluronan, At The AAOS Annual Meeting In Orlando

  2/25/2016

• Fidia Farmaceutici, S.p.A. Presents Hymovis, A New Generation Hyaluronan, At The American College of Rheumatology Annual Meeting In San Francisco

  11/2/2015

• Fidia Farmaceutici, S.p.A. Enters The Italian Pediatric Market Segment

  7/2/2015

• Fidia Farmaceutici, S.p.A. To Attend The 32nd Annual J.P. Morgan Investors Healthcare Conference

  1/6/2014

• Fidia Farmaceutici, S.p.A. to Distribute and Promote HYALGAN(R) (sodium hyaluronate) for Treatment of Osteoarthritis

  9/26/2011

• Sanofi Release: HYALGAN(R) (sodium hyaluronate) Commercial Rights Transfer Back to Fidia Farmaceutici, S.p.A.

  9/15/2011

• Anika Therapeutics Buys Italian Firm, Fidia Farmaceutici, S.p.A. for $34 Million

  1/4/2010

• Fidia Farmaceutici, S.p.A. Release: Fidia Farmaceutici, S.p.A.'s European Patent on Cross-Linked Gel Slurries Has Been Entirely Revoked by the EPO Board of Appeal

  12/2/2008

• APR Applied Pharma Research S.A. Receive IND Approval From FDA for a New NSAID Matrix Patch Product

  11/17/2008

• Akorn, Inc. Signs A Definitive Agreement With Fidia Farmaceutici, S.p.A. To Develop Four ANDA Drug Products For Commercialization

  5/2/2006